BIOGEN INC. (BIIB) Risk Factors
Health CareLatest 10-Q filed Jul 29, 2026Source: SEC EDGAR
WealthWire extracted and classified 31 risk factors from BIOGEN INC.’s latest SEC filing, mapping each to a standardized risk taxonomy so they can be compared across every company and sector. The breakdown below shows how those disclosures distribute across risk categories.
Financial
7 factorsOperations & people
6 factorsMarket & business
5 factorsHealthcare & life sciences
4 factorsTechnology
4 factorsESG & reputation
3 factorsLegal & regulatory
2 factorsRecent key developments
Concrete developments — dated events, named agreements and instruments, legal proceedings — that BIOGEN INC. surfaced in its latest filing.
- In May 2026, completed acquisition of Apellis, which became a wholly-owned subsidiary.May 2026
- One of our contract manufacturers for IMRALDI and BENEPALI was acquired by a third party in 2024.2024
- Built a large-scale biologics manufacturing facility in Solothurn, Switzerland; approved by FDA for LEQEMBI and TYSABRI.
- OECD GloBE Model Rules and Pillar Two side-by-side package announced in January 2026.January 2026
- Most OBBBA provisions have effective dates in 2027 and 2028.2027 and 2028
- The Inflation Reduction Act (IRA) and OBBBA healthcare reforms are enacted.
- Delays in clinical trials relating to geopolitical instability related to Russia's invasion of Ukraine and the military conflict in the Middle East.
- The U.S. government has challenged some of our donations to third-party charities that provide patient assistance.
Go deeper on BIIB
This page shows the category breakdown of the latest filing. The WealthWire API and dashboard add the full risk-factor text, multi-year trends, sector comparisons, and CSV export — for BIIB and every other S&P 500 company.